Investment Thesis
Jazz Pharmaceuticals exhibits strong operational profitability and cash generation, but the dramatic 163.6% YoY decline in net income despite 4.9% revenue growth signals severe underlying operational challenges or significant one-time charges that undermine confidence in earnings quality. Elevated leverage (1.18x Debt/Equity) combined with weak returns on equity (6.5%) and assets (2.5%) suggest the company is struggling with capital efficiency and may face restructuring pressures.
Strengths
- Exceptional free cash flow generation of $388.5M with 36.3% FCF margin
- Strong gross margins (57.2%) and operating margins (31.5%) indicate pricing power in core business
- Adequate liquidity position with 2.04x current ratio and $1.8B cash on hand
- Robust interest coverage of 10.3x demonstrates debt serviceability despite leverage
Risks
- Unexplained 163.6% net income decline YoY contradicts revenue growth, indicating potential major impairments or restructuring charges
- Elevated debt-to-equity ratio of 1.18x constrains financial flexibility in pharmaceutical sector
- Modest 4.9% revenue growth combined with 6.5% ROE and 2.5% ROA suggests competitive pressures and poor capital deployment
- Data quality gap with missing total liabilities figure limits balance sheet transparency
Key Metrics to Watch
- Net income trend in subsequent quarters to determine if decline is temporary or structural
- Revenue growth acceleration targeting 8%+ to demonstrate market competitiveness
- Debt reduction pathway and timeline to bring Debt/Equity below 1.0x
Financial Metrics
Revenue
1.1B
Net Income
293.1M
EPS (Diluted)
$4.43
Free Cash Flow
388.5M
Total Assets
11.9B
Cash
1.8B
Profitability Ratios
Gross Margin
57.2%
Operating Margin
31.5%
Net Margin
27.4%
ROE
6.5%
ROA
2.5%
FCF Margin
36.3%
Balance Sheet & Liquidity
Current Ratio
2.04x
Quick Ratio
1.85x
Debt/Equity
1.18x
Debt/Assets
0.0%
Interest Coverage
10.26x
Long-term Debt
5.4B
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-07T09:25:11.104154 |
Data as of: 2026-03-31 |
Powered by Claude AI